Myteka (montelukast sodium), is a leukotriene receptor antagonist, acts selectively, specifically inhibiting the cysteinyl leukotriene receptor. It is orally active.
- Prophylaxis and treatment of chronic Asthma
- Prevention of day and night time asthma symptoms
- Treatment of Aspirin sensitive asthmatic patients
- Prevention of exercise induced bronchoconstriction
- Day and night time symptoms of seasonal and perennial allergic rhinitis
Dosage And Administration
In Children 6 months - 6 years of age
One Myteka 4mg sachet or 4mg chewable Tablet to be taken in every night.
In Children 6 years -14 years
One Myteka 5mg chewable tablet to be taken in every night.
In Adults 15 Years and above
One Myteka 10mg tablet to be taken in every night.
Concomitant Use with Bronchodilators
Myteka tablets and sachets can be co-prescribed with bronchodilators when asthma is not well managed with bronchodilators alone. However, the dose of bronchodilator can later be reduced after getting adequate clinical response with the combination.
Concomitant Use with Inhaled Corticosteroids
Myteka tablets and sachets can be co-prescribed with inhaled corticosteroids when asthma is not well managed with the latter alone. However, the dose of inhaled corticosteroids can afterwards be gradually reduced or tapered off completely after getting adequate clinical response with the combination. However, Myteka tablets and sachets should not be an abrupt replacement for inhaled steroids.
Myteka tablets and sachets may be taken irrespective of food. Myteka starts exhibiting its therapeutic effect in terms of control parameters within one day of commencement of therapy. Patients should continue using Myteka even during periods of exacerbation of asthma symptoms.
Use in old age and compromised renal/hepatic function
There is no need to adjust dose in elderly patients, renal dysfunction, or mild-to-moderate hepatic dysfunction.